Perspective on biotech

Blue Latitude Health|14th September 2017

Biotech companies operate in highly complex markets with extremely challenging regulatory constraints. As a creative marketing consultancy we are well positioned to cut through this noise and tackle challenges from all angles, offering leading strategic and creative solutions. 

Ahead of our upcoming report into strategic challenges and opportunities in the sector, we have been speaking to biotech experts to find out their perspective on the state of the industry. 

Here we explore some of their enlightening insights and reveal how the definition of biotech is changing as big pharma turns its research and development to biological therapies. 

Find out about: 

  • The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques
  • How to define a biotech company – is the current definition still valid?
  • Shaping the future of healthcare – solving four common challenges facing biotech companies today.

 

Five key trends in precision and personalised healthcare

Natasha Cowan|5th December 2019

Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies can position themselves as leaders at the forefront of these exciting innovations.

read more

Why aren't doctors using digital therapeutics?

Guest Blogger|29th November 2019

The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these tools by healthcare professionals is comparatively low. Senior User Experience Consultant Stewart Anderson explains why.

read more

Launch Excellence 2020

Blue Latitude Health|18th November 2019

In this publication, we explore what makes a successful pharma launch from developing insight that drives behaviour change to lean launches and multi-indication launches, as well as an evaluation of the CAR-T market.

read more